MetaCap

ImageneBio Inc. (IMA)

NASDAQ: IMAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

3.920.00 (0.00%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IMA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$48.83M
EPS (TTM)
-$2.11
52-week range
3.00 – 7.60
Day range
3.79 – 4.04
Volume / Avg
44.34K / 15.86K
Beta
—

52-week range

$3.00$7.60

IMA stock today

ImageneBio (IMA) closed at $3.92 on Nov 20, essentially unchanged from the prior close, versus the S&P 500's 3.70% decline. Volume was 2.8x the average at 44.34K shares, a sign of unusually heavy trading. Shares are 48.4% below their 52-week high of $7.60, set on Jan 30, 2026 and 30.7% above the 52-week low of $3.00, near the bottom of the past year's range.

IMA is down 43.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 44.9%. ImageneBio has posted a net loss over the last twelve months (EPS of -$2.11), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About ImageneBio

Company profile

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Kristin Yarema Ph.D.
Headquarters
San Diego, CA
Employees
18
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, ImageneBio generated $800,000 in revenue, down 77.1% from fiscal 2024, its first annual decline since 2024. ImageneBio reported a net loss of $45.3 million, compared with a loss of $36.6 million a year earlier. Operating margin was -6056.4%.

ImageneBio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$800.00K$3.50M$9.16M$15.62M$30.98M
Growth-77.14%-61.79%-41.35%-49.59%+237.01%
Net income$-45.35M$-36.57M$-68.17M$-68.77M$-34.12M
EPS (diluted)$-9.64$-22.10$-1.63$-1.90$-1.22

Analyst forecast

Forecast

Consensus (4 analysts)

none

Avg. price target

$18.00+359.18%

  • Strong buy 0
  • Buy 3
  • Hold 0
  • Sell 1
  • Strong sell 0

Target range

Low $2.00High $28.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.91 vs $-0.83
Surprise
-9.64%

ImageneBio peers

Health Care sector
IMA peer companies
CompanyPrice% ChgMarket capCompare
AVXLAnavex Life Sciences Corp.0.5915-11.39%$54.83Mvs IMA
GRMLGreenland Mines Ltd.2.99+2.75%$44.31Mvs IMA
CGTXCognition Therapeutics Inc.0.5822-3.06%$55.37Mvs IMA
ELOXEloxx Pharmaceuticals Inc.10.69-1.75%$43.69Mvs IMA
OKYOOKYO Pharma Limited1.07-7.76%$56.15Mvs IMA
CHRSCoherus Oncology Inc.0.3698-4.47%$57.15Mvs IMA
INKTMiNK Therapeutics Inc.8.02-6.85%$41.17Mvs IMA
ELUTElutia Inc. Class A0.9001+11.12%$39.96Mvs IMA

Indexes, lists and sector

ImageneBio stock FAQ

What is ImageneBio's stock price today?

IMA last traded at $3.92 as of Nov 20, 4:00 PM EST, up 0.00% on the day. Prices are delayed at least 15 minutes.

Does ImageneBio pay a dividend?

No. ImageneBio does not currently pay a regular cash dividend.

Who is ImageneBio's CEO?

Dr. Kristin Yarema Ph.D. is the chief executive officer of ImageneBio Inc., which has about 18 employees.

Has IMA ever split its stock?

Yes. The most recent IMA stock split was a 1-for-12 split on Jul 28, 2025.

What is the IMA 52-week high?

The 52-week high for IMA is $7.60 and the 52-week low is $3.00. The stock is currently 48.4% below its high.

Compare IMA